Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect Study of AKB-6548 in Healthy Adults
NCT02412449Phase 1Completed
- Sponsor
- Akebia Therapeutics
- Start
- Apr 2015
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vadadustat in anemia of chronic kidney disease (CKD-A) (3 arms), sponsored by Akebia Therapeutics. Primary endpoints: Area under the plasma concentration-time curve from 0 to last quantifiable concentration, Area under the concentration time curve from time 0 to infinity and 4 more. Started Apr 2015; status: completed.
02
Drugs
vadadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT02412449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02412449.